• employee-related expenses, including salaries, bonuses, benefits and stock-based compensation, severance costs and other related costs for those employees engaged in the research and development function;

filing / Aug 4, 2026 / receipt

recession or other economic crisis; (b) credit and capital markets volatility (and access to these markets, including by our suppliers and customers); (c) manufacturing supply disruption due to travel restrictions or other government actions; (d) disruptions in raw material supply, our manufacturing operations, or in our distribution and supply chain; and (e) our ability to conduct planned clinical trials and commerc

filing / Aug 4, 2026 / receipt

healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications.

filing / Aug 4, 2026 / receipt

The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:

filing / Aug 4, 2026 / receipt

In November 2025, the Company’s Board of Directors approved a reduction in force of approximately 65 % of the Company’s workforce (together with the October 2025 actions, the “2025 Restructuring”) to preserve capital while the Company evaluated potential mergers, asset sales, or other strategic transactions.

filing / Aug 4, 2026 / receipt

• employee-related expenses, including salaries, benefits and stock-based compensation, severance costs and other related costs for those employees engaged in the research and development function;

filing / May 15, 2026 / receipt

recession or other economic crisis; (b) credit and capital markets volatility (and access to these markets, including by our suppliers and customers); (c) manufacturing supply disruption due to travel restrictions or other government actions; (d) disruptions in raw material supply, our manufacturing operations, or in our distribution and supply chain; and (e) our ability to conduct planned clinical trials and commerc

filing / May 15, 2026 / receipt

healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications.

filing / May 15, 2026 / receipt

The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:

filing / May 15, 2026 / receipt

In November 2025, the Company’s Board of Directors approved a reduction in force of approximately 65 % of the Company’s workforce (together with the October 2025 actions, the “2025 Restructuring”) to preserve capital while the Company evaluated potential mergers, asset sales, or other strategic transactions.

filing / May 15, 2026 / receipt